重症监护入院后院外存活天数的结局评估:一项全国回顾性队列研究
该研究为新西兰全国回顾性队列研究,纳入2017年1月1日至2023年12月31日期间所有年龄超过18岁的ICU患者,共72,546例次入院记录与NMDS链接。计算DAOH30、DAOH90和DAOH180,中位数分别为15天(0–22)、72天(40–81)和160天(117–171)。DAOH90与年龄(ρ=-0.19, p<0.001)和APACHE II评分(ρ=-0.42, p<0.001)负相关,在接受有创通气、血管活性药物支持和肾脏替代治疗及重型颅脑损伤患者中更低。DAOH30在高APACHE II评分、重型颅脑损伤及接受肾脏替代治疗或气管造口患者中观察到地板效应(中位DAOH30为0天)。结论支持在ICU患者中使用DAOH,但DAOH30不太可能是一个合适的指标。
要点
- DAOH90与年龄(ρ=-0.19, p<0.001)和APACHE II评分(ρ=-0.42, p<0.001)呈负相关。
- 接受有创通气、血管活性药物支持、肾脏替代治疗及重型颅脑损伤患者DAOH90更低。
- 高APACHE II评分、重型颅脑损伤、肾脏替代治疗或气管造口患者中位DAOH30为0天,存在地板效应。
- DAOH30中位数为15天(0–22),DAOH90为72天(40–81),DAOH180为160天(117–171)。
- 住院和死亡超额风险达到基线的时间分别为37.3天和18.6天,但在某些患者亚组中延长。
适用人群与场景
- 纳入:2017年1月1日至2023年12月31日期间在新西兰所有年龄超过18岁入住ICU的患者。
- 数据来源:澳大利亚和新西兰重症监护学会(ANZICS)成人患者数据库(APD)与国家最小数据集(NMDS)链接。
研究设计与关键结果
- 研究类型:全国回顾性队列研究;样本量:72,546例次ICU入院记录链接至NMDS。
- DAOH中位数(IQR):DAOH30为15天(0–22),DAOH90为72天(40–81),DAOH180为160天(117–171)。
- DAOH90与年龄负相关(ρ=-0.19, p<0.001),与APACHE II评分负相关(ρ=-0.42, p<0.001)。
- 接受有创通气、血管活性药物支持、肾脏替代治疗及重型颅脑损伤患者DAOH90更低。
- 高APACHE II评分、重型颅脑损伤、肾脏替代治疗或气管造口患者中位DAOH30为0天(地板效应)。
- 住院和死亡超额风险达到基线的时间分别为37.3天和18.6天,但在某些患者亚组中延长。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为研究证据支持在ICU患者中使用DAOH作为结局指标,但DAOH30不太可能是一个合适的指标。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Days alive out of hospital (DAOH) is defined as the number of days a patient spends alive and out of hospital in a predefined period. Current understanding of the performance of this outcome measure in the intensive care (ICU) population is limited thus we aimed to investigate the relationship between DAOH and prognostic indicators in patients admitted to ICU and to compare the performance of DAOH at 30-days (DAOH30), 90-days (DAOH90) and 180-days (DAOH180). METHODS: In a retrospective cohort study, all patients aged over 18 years admitted to ICU in New Zealand between 1st January 2017 and 31st December 2023 were eligible for inclusion. DAOH was calculated using merged data from the Australian and New Zealand Intensive Care Society (ANZICS) Adult Patient Database (APD) and the National Minimum Dataset (NMDS) data. RESULTS: 72,546 admissions recorded in the ANZICS APD were linked to NMDS. Median (interquartile range [IQR]) DAOH30 was 15 days (0–22), median (IQR) DAOH90 was 72 days (40–81) and median (IQR) DAOH180 was 160 days (117–171). DAOH90 was negatively correlated with age (ρ= -0.19, p < 0.001) and Acute Physiology and Chronic Health Evaluation (APACHE) II score (ρ = -0.42 p < 0.001). DAOH90 was lower in patients receiving invasive ventilation, vasoactive support and renal replacement therapy and those admitted with severe traumatic brain injury (TBI). Lower median DAOH90 was associated with increased variation in outcome across multiple subgroups. A floor effect was observed for DAOH30 (with a median DAOH30 value of zero days) in patients with high APACHE II score, severe TBI and patients undergoing renal replacement therapy or tracheostomy insertion. The time for the excess hazard of hospitalisation and mortality to reach baseline were 37.3 and 18.6 days respectively but were prolonged in certain patient subgroups. CONCLUSIONS: Our study provides evidence to support the use of DAOH for patients admitted to ICU, however DAOH30 is unlikely to be a suitable measure.
参考来源
- Brown A, Boyle L, McArthur C, et al. Evaluation of days alive out of hospital as an outcome after intensive care admission: a national retrospective cohort study. Crit Care. 2026. PMID: 41765883. doi:10.1186/s13054-026-05846-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。